Atypical Hemolytic Uremic Syndrome (aHUS) is defined by thrombocytopenia, hemolytic anemia, and acute renal failure. FEIBA is a concentrate of inactivated and activated coagulation factors that has been classically used to establish hemostasis in those with hemophilia or acquired factor inhibitors. However, recently it has seen used off-label as an anticoagulant reversal therapy amongst the general population.

Herein, we report for the first time aHUS attributed to the administration of a single large dose of FEIBA for anticoagulation reversal treated with hemodialysis and four weekly doses of eculizumab to quell disease and achieve dialysis independence.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.